Hypermetropia
Conditions
Keywords
ReLEx, SMILE, Hyperopia, VisuMax, Small Incision Lenticule Extraction, Lenticule, Farsightedness
Brief summary
The correction of farsightedness using ReLEx SMILE for hyperopia is focus of this investigation. The objective is to evaluate the safety and effectiveness.
Detailed description
The VisuMax laser keratome is an ophthalmic surgical femtosecond laser intended for use in patients requiring corneal incisions. The cutting action of the VisuMax laser keratome is achieved through precise individual micro-photodisruptions of tissue, created by tightly focused, ultra-short pulses, delivered through a disposable applanation lens while fixating the eye under a low vacuum. ReLEx SMILE combines state-of-the-art femtosecond laser technology of the VisuMax with high-precision lenticule extraction to provide minimally invasive refractive correction. It is distinguished by its flapless, minimally invasive laser correction. A refractive lenticule is created in the intact cornea, but removed via a small incision. The changed form of the cornea corrects the refraction error. ReLEx SMILE for myopia is a well-established treatment with extensive supporting published evidence for efficacy and safety. It is CE marked and available since 2011; more than 1 Million procedures have been performed worldwide. The correction of farsightedness using ReLEx SMILE for hyperopia is focus of this investigation and is therefore not yet CE marked.
Interventions
PROCEDUREReLEx SMILE
the VisuMax femtosecond laser is used to cut a thin layer of corneal tissue that is removed through a small cut in the cornea
Sponsors
Carl Zeiss Meditec AG
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Normal corneal topography; * Predicted post-operative keratometry ≤51 D; * Contact lens wearers must stop wearing their contact lenses before baseline measurements according to local requirements of the clinic; * Patients should be able to understand the patient information and willing to sign an informed consent; * Patients should be willing to comply with all follow-up visits and the respective examinations; * Patients with hyperopia or hyperopia with astigmatism (attempted correction: sphere up to +6.00D, cylinder up to 5.00D and maximum hyperopic meridian up to +7.00D); * The corrected distance visual acuity should be 20/25 or better in each eye pre-operatively; * A difference between cycloplegic and manifest refractions of ≤1.00 D spherical equivalent in the eye to be treated;
Exclusion criteria
* The patients presenting at least one of the characteristics as described for
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Corrected Distance Visual Acuity (CDVA) | 12 months | CDVA in logMar |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| side effects | 12 months | distribution in percent |
| contrast sensitivity | 12 months | contrast sensitivities for all spatial frequencies (3, 6, 12 and 18 cpd) in logMar |
| patient satisfaction (Quality of Vision Questionnaire) | 12 months | Mean +/- standard deviation |
| manifest refractive astigmatism | 12 months | Astigmatism in diopters \[D\] |
| spherical equivalent (SE) | 12 months | SE in diopters \[D\] |
Countries
China, Czechia, France, Germany, India, United Kingdom
Outcome results
None listed